Andres Forero

Andres Forero

UNVERIFIED PROFILE

Are you Andres Forero?   Register this Author

Register author
Andres Forero

Andres Forero

Publications by authors named "Andres Forero"

Are you Andres Forero?   Register this Author

85Publications

3174Reads

34Profile Views

Histone deacetylase inhibition promotes intratumoral CD8 T-cell responses, sensitizing murine breast tumors to anti-PD1.

Cancer Immunol Immunother 2019 Dec 12;68(12):2081-2094. Epub 2019 Nov 12.

Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 1720 2nd AVE S, Birmingham, AL, 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02430-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879872PMC
December 2019

The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth.

Cancer Immunol Immunother 2019 Feb 17;68(2):175-188. Epub 2018 Oct 17.

Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, 1720 2nd AVE S, SHEL 507, Birmingham, AL, 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-018-2262-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504180PMC
February 2019

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

N Engl J Med 2018 Nov;379(18):1711-1721

From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1807315DOI Listing
November 2018

Modulation of antitumor immunity with histone deacetylase inhibitors.

Immunotherapy 2017 12;9(16):1359-1372

Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA, 35233.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2017-0134DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077764PMC
December 2017

Physical Activity and Sleep Quality in Breast Cancer Survivors: A Randomized Trial.

Med Sci Sports Exerc 2017 Oct;49(10):2009-2015

1Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL; 2Faculty of Physical Education and Recreation, University of Alberta, Edmonton, Alberta, CANADA; 3Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; 4Department of Kinesiology, Southern Illinois University Carbondale, Carbondale, IL; 5Statistics and Research Informatics Core, Center for Clinical Research, Southern Illinois University School of Medicine, Springfield, IL; and 6Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1249/MSS.0000000000001327DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600650PMC
October 2017

The landscape of new drugs in lymphoma.

Nat Rev Clin Oncol 2017 Jun 29;14(6):335-346. Epub 2016 Dec 29.

UNMC Oncology/Haematology Division, 987680 Nebraska Medical Center, Omaha, Nebraska 681980-7680, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5611863PMC
June 2017

First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.

Invest New Drugs 2017 06 3;35(3):298-306. Epub 2017 Jan 3.

Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0420-1DOI Listing
June 2017

Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.

J Clin Oncol 2017 Mar 21;35(7):751-758. Epub 2016 Nov 21.

Kala Visvanathan, Johns Hopkins University School of Medicine and Bloomberg School of Public Health; MaryJo S. Fackler, Zhe Zhang, Zoila A. Lopez-Bujanda, Stacie C. Jeter, Lori J. Sokoll, Leslie M. Cope, Christopher B. Umbricht, David M. Euhus, Saraswati Sukumar, and Antonio C. Wolff, Johns Hopkins University School of Medicine, Baltimore, MD; Elizabeth Garrett-Mayer, Medical University of South Carolina, Charleston, SC; Andres Forero, University of Alabama at Birmingham, Birmingham, AL; Anna M. Storniolo, Indiana University, Bloomington, IN; Rita Nanda, University of Chicago, Chicago, IL; Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA; Lisa A. Carey, University of North Carolina, Chapel Hill, NC; and James N. Ingle, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.2080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455421PMC
March 2017

NCCN Guidelines Insights Breast Cancer, Version 1.2016.

J Natl Compr Canc Netw 2015 Dec;13(12):1475-85

From Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Washington/Seattle Cancer Care Alliance; UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Mayo Clinic Cancer Center; Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; Massachusetts General Hospital Cancer Center; Duke Cancer Institute; Vanderbilt-Ingram Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Michigan Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center; Roswell Park Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Research Advocacy Network; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; Stanford Cancer Institute; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0176DOI Listing
December 2015

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

J Clin Oncol 2015 May 6;33(14):1609-19. Epub 2015 Apr 6.

Denise A. Yardley, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Robert Weaver, Florida Cancer Specialists, Tampa, FL; Michelle E. Melisko, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco; Scott Cruickshank, Scott Cruickshank & Associates, Santa Barbara; Agustin A. Garcia, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA; Mansoor N. Saleh, Georgia Cancer Specialists, Sandy Springs, GA; Francis P. Arena, New York University Langons Arena Oncology, Lake Success; Tessa Cigler and Linda T. Vahdat, Weill Cornell Medical College, New York, NY; Andres Forero, University of Alabama, Birmingham, AL; Alison Stopeck, University of Arizona Cancer Center, Tucson, AZ; Dennis Citrin, Cancer Treatment Centers of America/Midwestern Regional Medical Center, Zion; Ira Oliff, Orchard Healthcare Research, Skokie, IL; Rebecca Bechhold, Oncology Hematology Care, Cincinnati, OH; Randa Loutfi, Henry Ford Health System, Detroit, MI; and Elizabeth Crowley, Jennifer Green, Thomas Hawthorne, Michael J. Yellin, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.2959DOI Listing
May 2015

Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.

Ann Hematol 2015 Apr 30;94(4):633-41. Epub 2015 Jan 30.

Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-014-2269-8DOI Listing
April 2015

PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.

Breast Cancer Res Treat 2015 Apr 2;150(3):569-79. Epub 2015 Apr 2.

Department of Radiation Oncology, University of Alabama at Birmingham, 1700 6th Avenue South, 176F HSROC Rm 2232 N, Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3359-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396624PMC
April 2015

Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).

BioDrugs 2014 Jun;28(3):253-63

Division of Hematology/Clinical Oncology, Department of Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, NP 2540M, 1802 6th Avenue South, Birmingham, AL, 35294-3300, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40259-014-0085-2DOI Listing
June 2014

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

J Clin Oncol 2014 Apr 24;32(12):1202-9. Epub 2014 Mar 24.

Ingrid A. Mayer, Vandana G. Abramson, Justin M. Balko, María Gabriela Kuba, Melinda E. Sanders, and Carlos L. Arteaga, Vanderbilt University, Nashville, TN; Steven J. Isakoff, Massachusetts General Hospital, Boston, MA; Andres Forero, University of Alabama, Birmingham, AL; Jeffrey T. Yap, Huntsman Cancer Institute, Salt Lake City, UT; Annick D. Van den Abbeele and Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Yisheng Li, MD Anderson Cancer Center, Houston, TX; and Lewis C. Cantley, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/03/18/JCO.2013.54
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.54.0518
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.0518DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986383PMC
April 2014

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.

Clin Cancer Res 2013 Oct 21;19(19):5505-12. Epub 2013 Aug 21.

Authors' Affiliations: Breast Cancer Medicine Service, Departments of Pathology, Biostatistics, and Radiology, Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University, New York; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, Massachusetts; Mayo Clinic, Rochester, Minnesota; Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia; University of North Carolina at Chapel Hill, Chapel Hill; Duke University Medical Center, Durham, North Carolina; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California; University of Alabama at Birmingham, Birmingham, Alabama; and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-3327DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086643PMC
October 2013

A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancer.

Semin Oncol 2013 Apr;40(2):135-44

Department of Radiation Oncology, Regional Cancer Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2013.01.010DOI Listing
April 2013

Effect of anti-DR5 and chemotherapy on basal-like breast cancer.

Breast Cancer Res Treat 2012 Jun 7;133(2):417-26. Epub 2011 Sep 7.

Department of Radiation Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294-2182, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-011-1755-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613128PMC
June 2012

By the pricking of my thumbs, something wicked this way comes: sporadic cancers versus eponymous hereditary cancer predisposition syndromes.

J Natl Compr Canc Netw 2012 Jan;10(1):7-13

Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, 1530 Third Avenue South, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2012.0004DOI Listing
January 2012

Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy.

Clin Breast Cancer 2011 Oct 10;11(5):312-9. Epub 2011 Aug 10.

Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35243, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15268209110011
Publisher Site
http://dx.doi.org/10.1016/j.clbc.2011.06.007DOI Listing
October 2011

GenDrux: a biomedical literature search system to identify gene expression-based drug sensitivity in breast cancer.

BMC Med Inform Decis Mak 2011 May 5;11:28. Epub 2011 May 5.

Division of Research, Department of Genetics, Univ. of Alabama at Birmingham (UAB), USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1472-6947-11-28DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116456PMC
May 2011

Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.

Cancer Biother Radiopharm 2011 Feb;26(1):127-33

Department of Radiation Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

View Article

Download full-text PDF

Source
http://www.liebertpub.com/doi/10.1089/cbr.2010.0864
Publisher Site
http://dx.doi.org/10.1089/cbr.2010.0864DOI Listing
February 2011

Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.

J Nucl Med 2010 Jan 15;51(1):150-7. Epub 2009 Dec 15.

Department of Radiation Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.109.066597DOI Listing
January 2010

A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae.

J Nucl Med 2008 Feb 16;49(2):279-84. Epub 2008 Jan 16.

Department of Radiation Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35249, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.107.045021DOI Listing
February 2008

Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity.

Cancer Biother Radiopharm 2006 Dec;21(6):553-60

Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294-3300, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cbr.2006.21.553DOI Listing
December 2006

A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma.

Cancer Biother Radiopharm 2006 Dec;21(6):561-8

Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294-3300, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cbr.2006.21.561DOI Listing
December 2006

Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy.

Clin Lymphoma Myeloma 2006 Nov;7(3):236-8

Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham, Comprehensive Cancer Center, AL, USA.

View Article

Download full-text PDF

Source
November 2006

Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.

Cancer Biother Radiopharm 2005 Oct;20(5):467-78

Department of Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, 1824 Sixth Avenue South, Birmingham, AL 35294-3300, USA.

View Article

Download full-text PDF

Source
http://www.liebertpub.com/doi/10.1089/cbr.2005.20.467
Publisher Site
http://dx.doi.org/10.1089/cbr.2005.20.467DOI Listing
October 2005

Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.

J Nucl Med 2005 Apr;46(4):642-51

Department of Radiation Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Wallace Tumor Institute, Birmingham, Alabama 35294, USA.

View Article

Download full-text PDF

Source
April 2005

Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein.

Cancer Biother Radiopharm 2005 Feb;20(1):110-8

Department of Radiation Oncology, University of Alabama, Birmingham, AL 35249, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cbr.2005.20.110DOI Listing
February 2005

History of antibody therapy for non-Hodgkin's lymphoma.

Semin Oncol 2003 Dec;30(6 Suppl 17):1-5

Department of Medicine, Division of Hematology/Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, 35294-3300, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2003.10.002DOI Listing
December 2003

A novel monoclonal antibody design for radioimmunotherapy.

Cancer Biother Radiopharm 2003 Oct;18(5):751-9

Department of Medicine, Division of Hematology/Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/108497803770418292DOI Listing
October 2003